The company manufactures large-scale plastic injection-molded automotive parts like bumpers and instrument panels, primarily serving Maruti Suzuki India Limited as a joint venture partner.
The company's competitive advantage is derived from its joint venture status with Maruti Suzuki, which provides captive demand; however, the lack of pricing power is evident in the extremely low net margins (0.4%) and poor ROCE (5.3%), suggesting the company operates more as a cost-center for its primary customer than a high-moat business.
Capital has been deployed into expanding capacity, including a new plant in Kharkhoda, yet these investments have failed to generate meaningful returns for shareholders, as evidenced by a negative EPS CAGR despite double-digit revenue growth.
The company collapsed under the weight of its own capital structure as interest rates rose while margins remained razor-thin. Despite growing revenues, the Kharkhoda expansion failed to generate returns above the cost of capital, turning the business into a 'growth trap' where more volume simply led to more debt. The unresolved regulatory inquiry eventually uncovered governance lapses that spooked lenders, and the primary customer squeezed pricing further to protect their own margins, leaving shareholders with a hollowed-out shell that prioritizes promoter salaries over equity returns.
RichFakir rates Machino Plastics Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Machino Plastics Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Machino Plastics Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Machino Plastics Ltd's fair value is about ₹43 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →